Results 31 to 40 of about 2,804,111 (259)

A prospective real-world analysis of erenumab in refractory chronic migraine

The Journal of Headache and Pain, 2020
Background Clinical trials have shown the safety and clinical superiority of erenumab compared to placebo in chronic migraine (CM). The aim of this analysis is to evaluate the effectiveness and tolerability of erenumab in a real-world setting in patients
G. Lambru, B. Hill, M. Murphy, I. Tylova, A. Andreou   +4 more
semanticscholar   +1 more source

Correlation of vestibular symptoms and headache in migraine patients: a clinical study of 424 cases

Di-san junyi daxue xuebao, 2021
Objective To evaluate the correlation between vestibular symptoms and headache in patients with migraine, and to explore the diagnostic value of vestibular symptoms in migraine.
LIU Juan, PAN Qi, ZHANG Yun, FAN Yulan, FAN Xiaoping, ZHANG Yixin, ZHOU Jiying   +6 more
doaj   +1 more source

Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. [PDF]

, 2016
BACKGROUND: Refractory migraine is a challenging condition with great impact on health related quality of life. Intravenous (IV) ketamine has been previously used to treat various refractory pain conditions.
Ashina, Sait, Lauritsen, Clinton, Lipton, Richard B., Mazuera, Santiago   +3 more
core   +3 more sources

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review

Headache, 2020
To review the literature on the mechanism of action of onabotulinumtoxinA in chronic migraine.
R. Burstein, A. Blumenfeld, S. Silberstein, Aubrey Manack Adams, M. Brin   +4 more
semanticscholar   +1 more source

Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety

Toxins, 2015
Background: Chronic migraine is a common, highly disabling, underdiagnosed and undertreated entity of migraine. It affects 0.9%–2.2% of the general adult population.
Délia Szok, Anett Csáti, László Vécsei, János Tajti   +3 more
doaj   +1 more source

Migraine and cluster headache show impaired neurosteroids patterns [PDF]

, 2019
Background: Perturbation of neuronal excitability contributes to migraine. Neurosteroids modulate the activity of γ-aminobutyric acid A and N-methyl-d-aspartate receptors, and might be involved in the pathogenesis of migraine.
Capi, M., Cicione, C., De Marco, C. M., Di Menna, L., Guglielmetti, M., Koverech, A., Lionetto, L., Maestri, M., Martelletti, P., Negro, A., Nicoletti, F., Passariello, F., Sabbatini, E., Simmaco, M.   +13 more
core   +1 more source

Depression is not the only cause of cognitive impairment in chronic migraine

Нервно-мышечные болезни, 2019
Background. Patients with the chronic migraine frequently present with memory and attention complaints. However, the prevalence and phenotype of such impairment in chronic migraine have not been studied.Objective – to evaluate the prevalence of the ...
N. V. Latysheva, E. G. Filatova, D. V. Osipova   +2 more
doaj   +1 more source

Induction of chronic migraine phenotypes in a rat model after environmental irritant exposure [PDF]

, 2017
Air pollution is linked to increased emergency department visits for headache and migraine patients frequently cite chemicals or odors as headache triggers, but the association between air pollutants and headache is not well understood.
Hurley, Joyce Harts, Johnson, Philip Lee, Kunkler, Phillip Edward, Oxford, Gerry Stephen, Zhang, LuJuan   +4 more
core   +1 more source

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience

The Journal of Headache and Pain, 2020
Background erenumab was safe and effective in clinical trials for the prevention of migraine. However, real-life data are still lacking. Here we report the clinical experience from an Italian real-world setting using erenumab in patients with chronic ...
A. Russo, M. Silvestro, Fabrizio Scotto di Clemente, F. Trojsi, A. Bisecco, S. Bonavita, A. Tessitore, G. Tedeschi   +7 more
semanticscholar   +1 more source

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study

Headache, 2021
To evaluate the efficacy of fremanezumab in patients with chronic migraine (CM) and moderate to severe depression.
R. Lipton, Joshua M. Cohen, M. Galić, M. Seminerio, P. Yeung, E. Aycardi, M. Bigal, K. Bibeau, D. Buse   +8 more
semanticscholar   +1 more source